RecruitingPhase 2NCT06518005

Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome

Studying Crigler-Najjar syndrome type 1

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Genethon
Principal Investigator: Philippe LABRUNE, MD, PHD
APHP_Hopital Antoine BECLERE
Intervention: Imlifidase(drug)
Enrollment: 3 enrolled
Eligibility: 18 years · All sexes
Timeline: 2024 – 2030

Study locations (1)

Hopital Antoine BECLERE, Clamart, France

Collaborators

Hansa Biopharma AB

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06518005 on ClinicalTrials.gov

← Back to all trials